LNTH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LNTH looks like a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. The stock has bullish technical momentum, supportive analyst upgrades with rising price targets, and upcoming presentation catalysts that can keep sentiment positive. Even though hedge funds and insiders are selling, the broader setup still favors buying now rather than waiting, especially since the user wants a direct entry decision and not an optimal-timing approach.
The current pre-market price is about 93.68, with the latest reported price at 94.47, which is near the pivot level of 94.873. Trend structure is constructive: SMA 5 is above SMA 20 and SMA 200, which confirms a bullish moving-average stack. MACD histogram is positive at 0.0501, though it is contracting, so momentum is positive but not accelerating strongly. RSI_6 at 57.959 is neutral-to-bullish, showing room for further upside without being overbought. Key levels to watch are support at 92.344 and resistance at 97.402. Overall, the technical picture supports a buy, with the stock still in an uptrend and not stretched.
Recent news is positive and event-driven. Lantheus will present new radiodiagnostic data at the SNMMI Annual Meeting on June 1-2, and it will also present LNTH-2403 data at ASCO on June 1, highlighting safety and preliminary anti-neoplastic activity in relapsed osteosarcoma. These are meaningful catalysts that can support investor interest. Analyst sentiment is also favorable, with several target hikes in early May and March reflecting confidence in PYLARIFY stabilization, multi-indication PET growth, and upside from future catalysts. The stock also has a favorable longer-term narrative around revenue and EPS growth beyond 2026.
The main negatives are insider and hedge fund selling trends, which are both significant in the provided data. Hedge funds have been selling more heavily and insiders have also been selling aggressively. Goldman Sachs remains neutral with a $94 target, which is close to the current price and suggests some analysts still see limited near-term upside. The MACD histogram is positive but contracting, so momentum is not perfectly strong. The short-term pattern data also shows only modest near-term performance expectations.
No usable quarterly financial snapshot was provided due to an error, so I cannot assess revenue, EPS, or margin trends directly from the latest quarter. However, analyst commentary indicates the company recently delivered another strong quarter with revenue and EPS comfortably ahead of expectations, led by PYLARIFY, Neuraceq, DEFINITY, and strategic partnerships. Commentary also notes PYLARIFY delivered its third consecutive beat and flat-to-up sequential revenue growth, which points to improving stabilization in the core business. Latest-quarter season appears to be the Q1 2026 earnings cycle based on the analyst notes.
Analyst sentiment is clearly constructive overall. Truist raised its target to $115 and kept Buy, Citizens raised to $115 and kept Outperform, Jefferies is at $110 with Buy, B. Riley is at $97 with Buy, and Mizuho is at $100 with Outperform. Goldman Sachs is more cautious with Neutral and a $94 target, but even that target is near the current price rather than bearish. The recent trend in ratings and targets is upward, with multiple firms raising targets after a strong quarter and highlighting stabilization in PYLARIFY and future growth catalysts. Wall Street's pros view is that LNTH has durable growth potential and multiple catalysts; the cons view is that valuation/growth execution and transition uncertainty still justify some caution.
